Coherence Neuro announces $45 million funding for experimental brain cancer implant

Coherence Neuro cofounder Ben Woodington calls the $45 million financing a Series A, while WIRED calls it a seed round. WIRED reports that the implant’s recording ability was briefly tested during tumor surgery in three people, with recording and stimulation testing in seven additional patients next. The company plans a long-term trial in patients with glioblastoma. Using the implant to detect and treat cancer remains the goal, not a reported clinical result.